Kairos Pharma, Ltd. · AMEX:KAPA

Kairos Pharma — Investor Presentation (March 2025)

24 slides from Kairos Pharma's investor presentation, March 2025

  1. Slide 1: Investor Presentation

    INVESTOR PRESENTATION NYSE American: KAPA kairospharma.com

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation may contain “forward-looking statements” regarding the current expectations and projections about future events of Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”). “Forward-looking statements” (statements as to matters other than historical facts)

  3. Slide 3: Our Mission

    OUR MISSION Kairos Pharma is dedicated to advancing therapies to overcome critical challenges in cancer drug resistance and immune suppression. 3

  4. Slide 4: Kairos Highlights

    KAIROS HIGHLIGHTS Experienced Team, Cedars Sinai to drive enrollment, Grant funding has created non-dilutive value Problem: Resistance develops for even blockbusters like androgen therapies, Tagrisso (NSCLC) Solution: CD105 elevated with resistance. Our INNOVATIVE antibody ENV 105 reverses resistanc

  5. Slide 5: ENV105: Overcoming Cancer Drug Resistance

    ENV105 OVERCOMING CANCER DRUG RESISTANCE THE PROBLEM: Cancers become resistant to the drugs that are used to treat them. CD105 is elevated in in resistant cancer cells. Anti-androgen drugs EGFR drugs (enzalutamide, (osimertinib, THE SOLUTION: abiraterone, apalutamide) erlotinib, gefitinib) ENV105 bl

  6. Slide 6: ENV105 in Prostate Cancer: Preclinical efficacy in resistant tumors

    ENV105 IN PROSTATE CANCER: Preclinical efficacy in resistant tumors ENV105 reverses resistance to enzalutamide. Left figure: Growing cancer cells with enzalutamide alone after resistance developed. Right figure: Dramatic reduction of cancer cells when ENV105 is added to enzalutamide Enzalutamide Enz

  7. Slide 7: ENV105 in Prostate Cancer: Clinical benefit and good safety

    ENV105 IN PROSTATE CANCER- Clinical benefit and good safety in patients progressing after 2 or more lines of Androgen receptor therapy. PREVIOUS PHASE 2 TRIAL RESULTS: 62% CLINICAL BENEFIT RATE Previous phase 2 trial tested whether ENV 105 could make prostate anti-androgen drugs work again when the

  8. Slide 8: ENV105 in Prostate Cancer: Biomarker to predict responsiveness

    ENV105 IN PROSTATE CANCER BIOMARKER TO PREDICT RESPONSIVENESS TO THERAPY • Biomarker is a genetic test that distinguishes between responsive and non-responsive patients • Identified biomarkers ensure more successful outcomes in new drug approval (NDA) success • $3.2 Million NIH grant to our CSO supp

  9. Slide 9: ENV105 in Prostate Cancer: Present randomized phase 2 trial

    ENV105 IN PROSTATE CANCER PRESENT RANDOMIZED PHASE 2 TRIAL Apalutamide with or without ENV105 Recurrence on anti-androgen Resistance to anti- drug androgen drugs PRIMARY ENDPOINT: Progression free survival SECONDARY ENDPOINT: Companion biomarker confirmation 9

  10. Slide 10: ENV105 in Lung Cancer

    ENV105 IN LUNG CANCER NON-SMALL CELL LUNG CANCER BECOMES RESISTANT TO OSIMERTINIB (TAGRISSO) Primary Mutations Resistance Mutations OSIMERTINIB RESISTANCE IS DEPENDENT ON CD105 • 45,000 EGFR driven NSCLC diagnosed last year • Tagrisso treats EGFR driven NSCLC • ENV 105 use to overcome NSCLC resistan

  11. Slide 11: ENV105 in Lung Cancer: Phase 1 trial

    ENV105 IN LUNG CANCER PHASE 1Mutations Primary TRIAL FOR EGFR-DRIVEN Resistance Mutations LUNG CANCER: Osimertinib (Tagrisso) + ENV105 Patients that have become resistant to Tagrisso Patients that are incompletely treated with Tagrisso (persistent ctDNA) PRIMARY ENDPOINT: Determine safety and effect

  12. Slide 12: KROS Drug Candidates: Overcoming Immune Suppression

    KROS DRUG CANDIDATES OVERCOMING IMMUNE SUPPRESSION Immunotherapy is a $118b market with only a 17% response rate. THE PROBLEM: Cancer is comprised of billions of growing cells. However, our immune system seldom generates enough T cells to kill all the cancer cells. THE SOLUTION: KROS drug candidates

  13. Slide 13: KROS101 expands T cells; KROS102 decreases T cells

    KROS101 expands T cells for cancer KROS102 decreases T cells for autoimmune diseases • KROS101 targets the GITR ligand and enables T cells to increase in numbers and kill cancer cells more effectively. • By increasing T cell numbers and function KROS101 may complement checkpoint inhibitors like pemb

  14. Slide 14: KROS101 GITR Agonist

    KROS101 GITR AGONIST v Immunity KROS 101: GITR (glucocorticoid-induced tumor necrosis factor Kairos identified structure of receptor) ligand is a powerful checkpoint that increases the T cell GITR ligand through X ray response against cancer. crystallography. Kairos Pharma developed a small molecule

  15. Slide 15: KROS102 GITR Antagonist

    KROS102 GITR ANTAGONIST Immunity • KROS102: GITR antagonist that decreases T cell numbers Kairos identified structure of and activity. GITR ligand through X ray • KROS-102 has been shown to decrease T effector cells (killer crystallography. T cells) and increase Treg cells (inhibitory T cells) which

  16. Slide 16: Portfolio of Innovative Drugs

    PORTFOLIO OF INNOVATIVE DRUGS DRUG MODALITY/ PHASE 1 PHASE 2 PHASE 3 LEAD INDICATION LEAD IDENTIFICAITON PRE-CLINICAL MARKET CANDIDATE MOA CLINICAL TRIALS CLINICAL TRIALS CLINICAL TRIALS Drug Screen Efficacy Toxicity Antibody targeting CD105 to Discovery Testing Testing reverse resistance to anti- a

  17. Slide 17: Cancer Drug Resistance Market

    Cancer Drug Resistance Market ENV105 MARKET OPPORTUNITY BY DISEASE - 2024 ENV105 MARKET OPPORTUNITY BY DISEASE • Anti-androgen therapy prostate cancer market of $11.3 billion1. Apalutamide (Erleada $3B in 2024 sales Chemotherapy Cancer Market • EGFR based lung cancer therapy market of $14 billion2.

  18. Slide 18: Immuno-Oncology Market

    Immuno-Oncology Market Global immunotherapy market estimates show significant compounded growth with sales expectations ranging from USD 94.7 - 126.9 Billion by 2026, exhibiting a CAGR of up to 20.2% from 2020.2 MARKET DRIVERS • Increasing patient pool and higher mortality rate are augmenting the ne

  19. Slide 19: Milestones

    MILESTONES 2013-2021 2022 2023 2024 2025+ June 2013 – Spun-off from • Preclinical work for • KROS-101 GITR agonist • Phase I and II trials with • Safety data from Phase II trial Cedars-Sinai Medical Center ENV105 Prostate Cancer molecule and KROS-102 ENV 105 enrolling and Phase I trial Phase II, ENV

  20. Slide 20: Strong Intellectual Property Foundation

    STRONG INTELLECTUAL PROPERTY FOUNDATION IP extends to 2040 Key IP generated from Murali, Published patents Exclusive, worldwide rights to IP Bhowmick and Yu labs executed internationally licensed from Cedars Sinai Medical Center Pub # KROS101 KROS201 KROS301 KROS401 ENV105 PCT/US2019/045478 PCT/US20

  21. Slide 21: Leading Team

    LEADING TEAM John S. Yu, MD Ramchandran Murali, Ph.D VP, RESEARCH AND DEVELOPMENT CEO & CHAIRMAN Professor, Biomedical Sciences and Research in Immunology at Professor of Neurosurgery, Director Surgical Neuro- Penn/Cedars-Sinai Medical Center. Oncology at Cedars-Sinai Medical Center • BAS from Stanf

  22. Slide 22: Independent Directors

    INDEPENDENT DIRECTORS Rahul Singhvi, Sc.D. Michael Keyoung, MD, Ph.D MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering Chemical engineering from MIT. MBA from the Wharton School of the (MSKCC), UCSF Health, Biomedical Fellow at Rockefeller and MSKCC University of Pennsylvan

  23. Slide 23: Kairos Pharma Summary

    Kairos Pharma SUMMARY • Clinical stage company with an antibody that impacts a central mechanism of CANCER DRUG RESISTANCE • Extensive pipeline targets IMMUNE SUPPRESSION • Enrolling in phase 1 and 2 trials with interim efficacy data in 2025 INNOVATIVE • Strategic relationship with Cedars-Sinai Medi

  24. Slide 24: Investor Relations

    INVESTOR RELATIONS Louie Toma MANAGING DIRECTOR CoreIR [email protected] NYSE American: KAPA kairospharma.com

Kairos Pharma — Investor Presentation (March 2025) on 6ix